MBCP Safety and Performance in the Osteonecrosis of Femur Head

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Biomatlante.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
CIC Bordeaux
Information provided by:
Biomatlante
ClinicalTrials.gov Identifier:
NCT00289575
First received: February 9, 2006
Last updated: March 1, 2007
Last verified: March 2007

February 9, 2006
March 1, 2007
February 2006
Not Provided
  • Infection and inflammation of the drilled area (blood and clinical assessment).
  • Adverse events.
Same as current
Complete list of historical versions of study NCT00289575 on ClinicalTrials.gov Archive Site
  • Pain (Analogic Visual Scale)
  • Hip function
  • Bone reconstruction evaluation through scanner and radiography
Same as current
Not Provided
Not Provided
 
MBCP Safety and Performance in the Osteonecrosis of Femur Head
Evaluation of Safety and Performance of Macroporous Biphasic Calcium Phosphate Granules Combined With Cellulosic-Derived Gel, in Filling Bones Gap After Aseptic Osteonecrosis Biopsy of Femur Head.

The aim of this pilot study is to evaluate MBCP performance in bone regeneration after osteonecrosis biopsy of the femur head. This technic may prevent the neck of the femur bone weakness following the healthy area drilling, thanks to a bone reconstruction at the expense of the biomaterial.

Twelve patients will be enrolled in this study and evaluation of infection and inflammation of the drilled area, pain and hip function will be assessed during a one year follow up. Bone reconstruction will be evaluated with scanner and radiography.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Osteonecrosis
Device: MBCP
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
12
February 2008
Not Provided

Inclusion Criteria:

  • femur head osteonecrosis (1 to 2 level in ARCO scale)
  • signed informed consent

Exclusion Criteria:

  • primary bone infection
  • femur head sphericity loss
  • cancer, diabetes, tuberculosis previous history
  • HIV, Hepatitis B, Hepatitis C infection
  • drepanocytosis
  • current corticotherapy
  • current immunosuppressive therapy
  • innate or acquired immune deficience
  • pregnancy or lack of efficient contraception
  • current participation in an other study
Both
18 Years to 50 Years
No
Contact: Thierry FABRE, Pr +33556795544 thierry.fabre@chu-bordeaux.fr
Contact: Dominique CHAUVEAUX, Pr +33556795679 dominique.chauveaux@chu-bordeaux.fr
France
 
NCT00289575
63
No
Not Provided
Biomatlante
CIC Bordeaux
Principal Investigator: Thierry FABRE, Pr Bordeaux University Hospital
Study Chair: Jacques DEMOTES-MAINARD, Pr Clinical Research Center INSERM/Bordeaux University Hospital
Biomatlante
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP